Neurotrophins are a family of secreted growth factors that regulate survival, growth, di erentiation and maintenance of neurons in both CNS and PNS [1] [2] [3] . Four neurotrophins, nerve growth factors (NGF) [4], brain-derived neurotrophic factor (BDNF) [5] , neurotrophin-3 (NT-3) [6] and neurotrophin-4/5 (NT-4/5) [7] have been identi ed and their function in the nervous system has been widely explored. The [12] , which mediate both unique and overlapping functions of neurotrophins in the CNS and PNS [13]. Thus there are multiple levels by which neurotrophin actions can be modulated to impact depression and the response to antidepressants, including regulation of their synthesis, secretion, and signaling, all of which are discussed below.
Is BDNF a biomarker of human depression?
Recognition by Duman and colleagues [14] that antidepressant treatment was associated with increased BDNF expression in the hippocampus led to further investigation of the role that neurotrophins play in depression and in the response to antidepressant treatment, both in human subjects and animal models of depression. Analysis of postmortem human brain tissues has revealed reduced BDNF mRNA and protein levels in hippocampus, prefrontal cortex and amygdala of depressed patients and suicide subjects [15] [16] [17] . Moreover, antidepressant treatments were found to increase BDNF protein levels in different areas of hippocampus [18] .
Given the limitations of human postmortem studies, BDNF levels in blood samples have been widely studied. Reduced levels of mature BDNF, but not its precursor proBDNF, were reported in sera and plasma from depressed patients [19] [20] [21] [22] , and this reduction of BDNF was normalized by antidepressant treatment [23] [24] [25] . In addition, reduced BDNF content in platelets and decreased BDNF mRNA expression in peripheral blood lymphocytes and mononuclear cells were also reported in depressed patients [26] [27] [28] . Reduced BDNF levels in both serum and plasma have also been found in depressed patients who have attempted suicide, compared to non-suicidal depressed patients or healthy controls, and in subjects with depressive episodes of longer Manipulation of BDNF expression in animal models with regional speci city should therefore provide insight into potential mechanisms that underlie major depressive disorder in humans, and these studies are described below. [12] . Phosphorylation of Y490 of TrkB leads to recruitment of adaptor proteins such as Shc, Grb2 and Gab1 and subsequent activation of the PI3K/Akt pathway [192] and Rho family of GTPases (RhoA, Rac, Cdc42), which positively regulate actin polymerization through downstream signaling including ROCK/PAK, LimK and Cofilin [151] [152] [153] . Another downstream effector of the PI3K/Akt pathway is GSK-3, whose activity is negatively regulated by Akt-mediated phosphorylation [193] . One of the downstream targets of GSK-3 is β-catenin, which can be translocated into the nucleus to promote gene expression. The mTOR pathway, which facilitates local translation and the rapid antidepressant effects of ketamine, is also regulated by PI3K/Akt signaling [122] . Activation of PI3K/Akt signaling is believed to positively modulate spinogenesis, synaptogenesis and neurogenesis, thus inducing antidepressant effects. In addition to inductive effects on gene expression, the Ras/ERK (MAPK) pathway also acts through Rho family of GTPases, mTOR signaling, and synapsin to induce spinogenesis, synaptogenesis and neurogenesis (not shown) [122, 153, 154] . Phosphorylation of Y816 of TrkB recruits PLCΥ [194] , inducing the hydrolysis of PIP2 to IP3 and DAG. IP3 regulates calcium release and CAMK activation, while DAG activates PKC. Both IP3/CAMK and DAG/PKC signaling regulate synaptic plasticity [195] , however their roles in depression remain largely unknown.
What role does BDNF play in antidepressant treatment?

Behavioral e ects of BDNF downregulation
ERK signaling in depression and antidepressant efficacy, hippocampal overexpression of MAPK Phosphatase-1 (MKP-1), a negative regulator of the MAPK pathway, induced depressive behavior, while local deletion of MKP-1 in hippocampus led to a resilient response to stress [113] . And as noted previously, the effects of BDNF signaling pathways on depression and antidepressant efficacy are location-dependent: chronic unpredictable stress promoted ERK signaling in VTA [114] , while viral-mediated overexpression of ERK2 in VTA increased susceptibility to stress and ERK2 blockade in VTA produced resilience [114] .
Studies of PI3K/Akt signaling in the brain provide further evidence for its modulation of depressive behavior, but a simple, region-specific pattern of signaling pathway contributions to depression does not emerge. Reduced Akt signaling has been found in hippocampus and prefrontal cortex of depressed and suicide subjects [115, 116] , and in animals, chronic social defeat stress and chronic unpredictable stress reduced Akt phosphorylation in the VTA [117, 118] , while viral-mediated blockade of Akt signaling in VTA increased susceptibility to social defeat-induced depressive behavior [118] .
Recently, decreased Akt phosphorylation was also observed in basolateral amygdala following FST [119] , suggesting that a generalized decrease in Akt signaling is associated with depression, distinct from region-specific ERK2 signaling described above. Lastly, blockade of the PI3K/ Akt pathway was su cient to o set increased hippocampal neurogenesis following exercise [120] , and to prevent the antidepressant-like e ects of folic acid [121] and ketamine [122] . Since BDNF acts through the PI3K/Akt pathway (see protein levels were observed in ventral prefrontal cortex of depressed subjects [115, 125] , and a GSK-3β polymorphism has been correlated with altered hippocampal structure in depressed patients [126] . In rodent studies, intraperitoneal and intracerebroventricular administration of
GSK-3 inhibitors induces antidepressant-like
behaviors [127, 128] . Similar antidepressantlike effects were also observed in both GSK-3α
and GSK-3β deficient mice [129, 130] . Moreover, How do neurotrophins and their signaling pathways modulate depressive behavior?
Regulation of neuronal plasticity
Disruption of neuronal plasticity has been linked to impaired learning and memory, as well as mood disorders such as major depression and bipolar disorder [135] . Clinical evidence has supported reduced hippocampal volumes in depressed patients [136] [137] [138] [139] [140] [141] , while animal studies provide related data demonstrating that stress induces retraction of pyramidal cell dendrites in hippocampus [77, 142] , and the loss of pyramidal neuron dendritic spines in medial prefrontal cortex [143, 144] . Working in an opposing manner, antidepressant treatments, including ECT and drugs, increase plasticity by inducing hippocampal dendritic sprouting [145] , increasing dendritic spine density [146] , and promoting synaptogenesis [147] . is su cient to increase dendritic complexity and soma size as well as to induce production of filopodia-like protrusions, whereas mTOR inhibition has the opposite e ects [150] .
In addition, Ras/ERK (MAPK) and PI3K/Akt pathways are believed to be upstream of Rho family GTPases, including RhoA, Rac and Cdc42, which are involved in the regulation of actin polymerization, thus mediating dendritic spine plasticity [151] [152] [153] . Ras/ERK (MAPK) and PI3K/ Akt pathways were also demonstrated to be necessary for ketamine-induced activation of mTOR signaling, which is functionally correlated with synapse formation [122] . Lastly, Ras/ERK (MAPK) pathway-dependent phosphorylation of synapsin regulates synaptogenesis [154] .
Many of the pro-depressant and antidepressant effects of BDNF are therefore mediated by signaling pathways downstream of the TrkB receptor that impact the plasticity of neural circuits in a regionally-specific manner.
Regulation of neurogenesis
Malberg and Duman first reported that fluoxetine could reverse the stress-induced reduction in hippocampal neurogenesis [155] , establishing a correlation between neurogenesis and depression. Impaired neurogenesis in hippocampus, caused by irradiation, prevented the antidepressant effects of fluoxetine and imipramine, which were observed in non-irradiated controls [156] . These ndings were supported by several subsequent studies [157, 158] , although neurogenesisindependent e ects of antidepressant treatment were also suggested [159] . neurons [162] . On the other hand, viralmediated BDNF overexpression was sufficient to enhance hippocampal neurogenesis [163] , and intraventricular and intrahippocampal
BDNF infusions increased neurogenesis in
rat olfactory bulb [164] and hippocampus [165] , respectively, while intravenous BDNF administration in a rat stroke model increased neurogenesis in the dentate gyrus and improved recovery [166] .
In addition to BDNF, NT-3 deletion in dentate gyrus reduced the number of di erentiated hippocampal progenitor cells [167] , while intracerebroventricular NGF infusion promoted survival of newborn neurons in adult dentate gyrus [168] . was also observed in the medial prefrontal cortex of mice that were susceptible to chronic social defeat [185] , and also in three rodent models that manifest depressivelike behavior [184, 186, 187] . and stabilization [190] in the hippocampus, was sufficient to block the antidepressant-like effects in the FST caused by BDNF infusion into dentate gyrus [191] , indicating that the antidepressant-like effects of BDNF may also depend on other regulators of synaptic plasticity including neuritin.
Conclusions
Neurotrophins in general and BDNF in particular 
